A detailed history of Black Rock Inc. transactions in Glaukos Corp stock. As of the latest transaction made, Black Rock Inc. holds 7,897,030 shares of GKOS stock, worth $935 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
7,897,030
Previous 7,894,315 0.03%
Holding current value
$935 Million
Previous $628 Million 18.66%
% of portfolio
0.02%
Previous 0.02%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$76.4 - $96.33 $207,426 - $261,535
2,715 Added 0.03%
7,897,030 $745 Million
Q4 2023

Feb 13, 2024

SELL
$59.53 - $85.11 $330,153 - $472,020
-5,546 Reduced 0.07%
7,894,315 $628 Million
Q3 2023

Nov 13, 2023

SELL
$69.23 - $79.09 $104,952 - $119,900
-1,516 Reduced 0.02%
7,899,861 $594 Million
Q2 2023

Aug 11, 2023

BUY
$45.44 - $71.21 $6.65 Million - $10.4 Million
146,277 Added 1.89%
7,901,377 $563 Million
Q1 2023

May 12, 2023

SELL
$43.88 - $52.48 $1.26 Million - $1.51 Million
-28,694 Reduced 0.37%
7,755,100 $389 Million
Q4 2022

Feb 13, 2023

BUY
$40.82 - $57.75 $5.6 Million - $7.92 Million
137,221 Added 1.79%
7,783,794 $340 Million
Q3 2022

Nov 14, 2022

BUY
$46.84 - $58.49 $5.76 Million - $7.2 Million
123,027 Added 1.64%
7,646,573 $407 Million
Q2 2022

Aug 12, 2022

BUY
$34.86 - $63.77 $1.99 Million - $3.64 Million
57,014 Added 0.76%
7,523,546 $342 Million
Q1 2022

May 12, 2022

BUY
$44.33 - $57.82 $1.9 Million - $2.48 Million
42,830 Added 0.58%
7,466,532 $432 Million
Q4 2021

Feb 10, 2022

BUY
$40.27 - $56.99 $12.3 Million - $17.5 Million
306,284 Added 4.3%
7,423,702 $330 Million
Q3 2021

Nov 09, 2021

SELL
$47.43 - $84.23 $2.99 Million - $5.31 Million
-63,048 Reduced 0.88%
7,117,418 $343 Million
Q2 2021

Aug 11, 2021

BUY
$73.06 - $97.7 $525 Million - $702 Million
7,180,466 New
7,180,466 $609 Million

Others Institutions Holding GKOS

About GLAUKOS Corp


  • Ticker GKOS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 47,596,900
  • Market Cap $5.63B
  • Description
  • Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-...
More about GKOS
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.